These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III. Denman RB; Smedman M; Kung L Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Bramlage B; Luzi E; Eckstein F Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100 [TBL] [Abstract][Full Text] [Related]
8. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Phylactou LA; Tsipouras P; Kilpatrick MW Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217 [TBL] [Abstract][Full Text] [Related]
9. The effect of structure in a long target RNA on ribozyme cleavage efficiency. Campbell TB; McDonald CK; Hagen M Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806 [TBL] [Abstract][Full Text] [Related]
11. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Amarzguioui M; Brede G; Babaie E; Grotli M; Sproat B; Prydz H Nucleic Acids Res; 2000 Nov; 28(21):4113-24. PubMed ID: 11058107 [TBL] [Abstract][Full Text] [Related]
13. Low-magnesium, trans-cleavage activity by type III, tertiary stabilized hammerhead ribozymes with stem 1 discontinuities. Burke DH; Greathouse ST BMC Biochem; 2005 Aug; 6():14. PubMed ID: 16095542 [TBL] [Abstract][Full Text] [Related]
14. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake. Bramlage B; Alefelder S; Marschall P; Eckstein F Nucleic Acids Res; 1999 Aug; 27(15):3159-67. PubMed ID: 10454613 [TBL] [Abstract][Full Text] [Related]
16. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500 [TBL] [Abstract][Full Text] [Related]
17. Intermolecular cleavage by the newt ribozyme. Marusic L; Luzi E; Barsacchi G; Eckstein F Eur J Biochem; 1997 Jul; 247(1):396-401. PubMed ID: 9249052 [TBL] [Abstract][Full Text] [Related]
18. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection. Tang J; Breaker RR RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650 [TBL] [Abstract][Full Text] [Related]